BRCA突变乳腺癌患者的生殖潜力与生育力保存策略表现
该研究回顾性分析了两项前瞻性研究中的156例新发早期乳腺癌患者,比较BRCA突变与否者的基线AMH及冻存策略表现。BRCA突变者AMH中位数1.8 μg/l vs 无突变者2.6 μg/l(P=0.109),卵母细胞冻存获卵数(6.5 vs 9,P=0.145)和冻存数(3.5 vs 6,P=0.121)呈减少趋势。结论为BRCA突变乳腺癌患者生殖潜力及冻存策略表现呈一致下降趋势,需独立验证。
要点
- BRCA突变乳腺癌患者AMH中位数1.8 μg/l,无突变者2.6 μg/l,差异无统计学意义(P=0.109)。
- 卵母细胞冻存中,BRCA突变者获卵数中位数6.5 vs 无突变者9(P=0.145),冻存数3.5 vs 6(P=0.121)。
- 卵巢组织冻存中,BRCA突变者每片段卵母细胞数0.08 vs 0.14(P=0.193),每平方毫米0.33 vs 0.78(P=0.153)。
核心结论
- BRCA突变乳腺癌患者生殖潜力及冻存策略表现呈一致下降趋势,需独立验证。
- BRCA1与BRCA2突变患者在上述结局中未见差异。
研究设计与样本
- 回顾性分析两项前瞻性研究(卵母细胞冻存和卵巢组织冻存)中的新发早期乳腺癌患者。
- 共纳入156例,101例已知BRCA状态,其中29例(18.6%)BRCA突变,72例(46.1%)无突变。
- 全队列中位年龄31岁(IQR 28-33)。
主要发现
- BRCA突变者AMH中位数1.8 μg/l(IQR 1.0-2.7),无突变者2.6 μg/l(IQR 1.5-4.1),P=0.109。
- 卵母细胞冻存(N=29)中,BRCA突变者获卵数中位数6.5 vs 无突变者9(P=0.145),冻存数3.5 vs 6(P=0.121)。
- 卵母细胞冻存中,获卵≤4枚的 poor response 率BRCA突变者40.0% vs 无突变者11.1%(P=0.147)。
- 卵巢组织冻存(N=72)中,BRCA突变者每片段卵母细胞数中位数0.08 vs 0.14(P=0.193),每平方毫米0.33 vs 0.78(P=0.153)。
- 2例BRCA突变患者化疗后移植,其中1例足月分娩健康婴儿。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. PATIENTS AND METHODS: This was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients. In the current analysis, baseline anti-Mullerian hormone (AMH) and performance of cryopreservation strategies were compared between patients with or without germline deleterious BRCA mutations. RESULTS: Out of 156 patients included, 101 had known BRCA status of whom 29 (18.6%) were BRCA-mutated and 72 (46.1%) had no mutation. Median age in the entire cohort was 31 years [interquartile range (IQR) 28-33). Median AMH levels were 1.8 μg/l (IQR 1.0-2.7) and 2.6 µg/l (IQR 1.5-4.1) in the BRCA-positive and BRCA-negative cohorts, respectively (P = 0.109). Among patients who underwent oocyte cryopreservation (N = 29), women in the BRCA-positive cohort tended to retrieve (6.5 versus 9; P = 0.145) and to cryopreserve (3.5 versus 6; P = 0.121) less oocytes than those in the BRCA-negative cohort. Poor response rate (i.e. retrieval of ≤4 oocytes) was 40.0% and 11.1% in the BRCA-positive and BRCA-negative cohorts, respectively (P = 0.147). Among patients who underwent ovarian tissue cryopreservation (N = 72), women in the BRCA-positive cohort tended to have a numerically lower number of oocytes per fragment (0.08 versus 0.14; P = 0.193) and per square millimeter (0.33 versus 0.78; P = 0.153) than those in the BRCA-negative cohort. Two BRCA-mutated patients were transplanted after chemotherapy and one delivered at term a healthy baby. No difference between BRCA1- and BRCA2-mutated patients was observed in any of the above-mentioned outcomes. CONCLUSION: A consistent trend for reduced reproductive potential and performance of cryopreservation strategies was observed in BRCA-mutated breast cancer patients. Independent validation of these results is needed.
引用
- Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018. PMID: 29045555. doi:10.1093/annonc/mdx639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。